預測食道癌存活及癒後狀態之方法及其套組及微陣列晶片

專利類型

發明

專利國別 (專利申請國家)

中華民國

專利申請案號

100137548

專利證號

I 429910

專利獲證名稱

預測食道癌存活及癒後狀態之方法及其套組及微陣列晶片

專利所屬機關 (申請機關)

高雄醫學大學

獲證日期

2014/03/11

技術說明

本發明成功使用一株國人食道扁平上皮細胞癌之細胞株，利用Transwell invasion chamber 技術篩選出不同侵襲能力之子代細胞株。藉著全基因微陣晶片尖端技術應用在此親代細胞株及最侵襲能力的子代細胞株，本發明發現13個具有潛力及創新並與分泌型及細胞膜相關之蛋白質。本發明確認2個蛋白質-- PI3(peptidase inhibitor 3)與CD14 antigen (CD14)表現與微矩陣晶片結果一致。另外，將其應用至臨床上各3個食道扁平上皮細胞癌—分別具有預後較好(平均存活約25個月)及預後較差(平均存活約7個月)之癌症病理組織上，發現兩群病人之PI3(peptidase inhibitor 3)與CD14 antigen (CD14)蛋白質表現量差異性極大，且病理組織之表現量的方向與細胞株的結果一致。因此，本發明之實驗結果支持PI3(peptidase inhibitor 3)與CD14 antigen (CD14)蛋白質可以預測早期食道扁平上皮細胞癌病人之預後及存活。 It is crucial to find potential novel genes that can predict the survival of esophageal cancer. We have successfully used the Transwell invasion chamber to subdivide the different invasive subpopulations from one Taiwanese esophageal squamous cell carcinoma (ESCC) cell line (CE81T). The invasive characteristics of the parental cell line and sublines were confirmed by a series of in-vitro and in-vivo studies. By applying the RNA expression array into these cell lines, we identified one panel of 13 potential genes with encoded extracellular or membrane proteins related to their invasiveness. We verified their functional expressions in the cell lines. Among them, we found the consistent findings of peptidase inhibitor 3 (PI3) and CD14 antigen (CD14) expressions in in-vitro study and also found distinct protein expressions of PI3 and CD14 in cancer tissues among 3 early-stage ESCC patients with good survival (~25 months) and another 3 ones with poor survival (~7 months).

備註

連絡單位 (專責單位/部門名稱)

智財保護與科技管理組

連絡電話

07-3138030

網址